A Study Comparing Insulin Intensification Therapies in Patients With Type 2 Diabetes Mellitus
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 402 participants.
Also called NCT01175811
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 402 participants
- Sponsor
- Registry
-
NCT01175811
-
- Other papers using this trial's data
- Comparison of thrice-daily premixed insulin (insulin lispro premix) with basal-bolus (insulin glargine once-daily plus thrice-daily prandial insulin lispro) therapy in east Asian patients with type 2 diabetes insufficiently controlled with twice-daily premixed insulin: an open-label, randomised, controlled trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- China, South Korea, Taiwan
- Registry status
- Completed
Technical summary
Registry record NCT01175811. Randomized; no masking; primary purpose treatment. Start 2011-02 (registry gives no type); primary completion 2012-11 (actual). Results posted on 2013-12-18.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study Comparing Insulin Intensification Therapies in Patients With Type 2 Diabetes Mellitus
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Insulin Lispro Premix
- Intervention (Drug)
- Insulin Glargine
- Intervention (Drug)
- Insulin Lispro
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct01175811- Content hash
075ab4f44e2686a4fa3904a82a8793a42ebf3245f35d54a5c5981f5c539496a9